Algorithmiq’s Quantum Breakthrough: Revolutionizing Cancer Treatment with Light-Sensitive Drugs

Algorithmiq, a quantum software company based in Helsinki, has emerged as the sole recipient of a €1.7 million ($2 million) prize from Wellcome Leap, a US nonprofit established by the Wellcome Trust to expedite advancements in human health.

The company clinched this prestigious award for being the exclusive participant to showcase the potential of quantum computing in simulating complex therapeutics, thereby paving the way for a plausible quantum advantage in health in the near future.

This accolade signifies the culmination of Wellcome Leap’s Quantum for Bio (Q4Bio) challenge, a €42.3 million ($50 million) initiative spanning 2.5 years that called upon research teams worldwide to exhibit applications of biology and healthcare on emerging quantum hardware.

According to Algorithmiq, the triumphant quantum computing framework was developed based on three essential criteria: feasibility on existing hardware, relevance to biologically significant systems, and validation against cutting-edge classical methods within practical resource constraints.

Aside from Algorithmiq, the finalists of the competition included teams spearheaded by Infleqtion, the University of Nottingham, Harvard University, Stanford University, and the University of Oxford.

Dr. Sabrina Maniscalco, the CEO and co-founder of Algorithmiq, expressed, “Algorithmiq stands as the first and only team in Q4Bio to present a scalable end-to-end computational framework that merges quantum computing and AI for authentic therapeutic challenges, demonstrated on up to 100 qubits. This showcases that quantum computing is already equipped to tackle scientifically pertinent drug development inquiries under real hardware limitations.”

Established in 2020 by Dr. Maniscalco, Guillermo García-Pérez (CSO), Matteo Rossi (CTO), and Boris Sokolov (lead researcher), Algorithmiq specializes in developing quantum software that maximizes the utility of quantum computers, facilitating breakthroughs in chemistry, materials science, and life sciences through physically meaningful and energy-efficient quantum computation.

Algorithmiq asserts that its comprehensive quantum-classical workflow for chemistry simulations was implemented using up to 100 qubits on IBM hardware to simulate the activation pathway of a photosensitizer drug currently undergoing Phase II clinical trials. The outcomes demonstrate a scalable trajectory towards achieving quantum advantage in drug discovery.

The company underscores that while numerous applications have been proposed for quantum computing, it remains uncertain whether this nascent technology surpasses classical state-of-the-art methods for these applications. Demonstrating the latter has been a primary challenge in the field over the past few decades. Algorithmiq contends that its findings establish that quantum computing can deliver substantial value for practical drug development and discovery, rather than abstract benchmarks.

The triumphant multidisciplinary team was spearheaded by quantum software company Algorithmiq, with quantum computing support from IBM, and biological expertise from the Cleveland Clinic. The project was overseen by Dr. Sabrina Maniscalco, with co-principal investigators Dr. Ivano Tavernelli of IBM and Dr. Vijay Krishna of the Cleveland Clinic. The initiative received backing from IBM and the Cleveland Clinic’s Quantum Innovation Catalyser program.

The winning team’s endeavors were centered on photodynamic therapy (PDT), an emerging cancer treatment that utilizes light-activated drugs to target and eliminate tumor cells. This approach offers significant benefits to patients, including reduced adverse effects compared to traditional therapies. The quest for new photosensitizers for PDT has been impeded by the absence of reliable data.

The team illustrated that such data can be efficiently acquired and integrated into an active learning AI loop to generate innovative drug candidates. The impact of this work extends beyond photodynamic therapy and is applicable to a wide array of use cases across healthcare and life sciences.

Dr. Vijay Krishna, the lead researcher at the Cleveland Clinic, remarked, “As the home of the first quantum computer dedicated to healthcare research, Cleveland Clinic played a vital role in defining and anchoring the biomedical challenge in clinically relevant scenarios. This recognition underscores the value of amalgamating that expertise with excellence in algorithm development and hardware. By enhancing our understanding of light-activated drug behavior, this work not only advances photodynamic therapy but also transcends to other light-dependent therapies, unlocking diverse applications across healthcare and life sciences.”

In addition to this accolade, Algorithmiq highlights several other accomplishments, including collaborations with Microsoft and IBM, and the launch of the Quantum Advantage Tracker (in partnership with IBM and its collaborators), an open, community-driven benchmark crafted to validate claims of quantum advantage.

Algorithmiq operates in Italy, Finland, the UK, Ireland, and the US.